Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Operating Expenses:
Research and development	$ 9,510	$ 6,632	$ 17,786	$ 10,817
General and administrative	4,306	2,169	8,841	3,911
Total operating expenses	13,816	8,801	26,627	14,728
Total operating loss	(13,816)	(8,801)	(26,627)	(14,728)
Other income (expense):
Change in fair value of warrant liability	61	(3)	16	1
Change in fair value of derivative liability		(52)		(52)
Interest income, including amortization and accretion income	292	4	319	3
Other expense	(5)	0	(11)	(3)
Total other income (expense)	348	(51)	324	(51)
Net loss	(13,468)	(8,852)	(26,303)	(14,779)
Net loss attributable to common stockholders - basic and diluted (Note 13)	$ (13,468)	$ (12,480)	$ (26,303)	$ (20,738)
Net loss per share attributable to common stockholders - basic	$ (0.46)	$ (28.53)	$ (0.90)	$ (49.49)
Net loss per share attributable to common stockholders - diluted	$ (0.46)	$ (28.53)	$ (0.90)	$ (49.49)
Weighted average common stock outstanding - basic	29,251,480	437,464	29,232,661	419,059
Weighted average common stock outstanding - diluted	29,251,480	437,464	29,232,661	419,059
Comprehensive loss:
Net loss	$ (13,468)	$ (8,852)	$ (26,303)	$ (14,779)
Other comprehensive items:
Unrealized loss on marketable securities	(123)		(128)
Total other comprehensive loss	(123)		(128)
Total comprehensive loss	$ (13,591)	$ (8,852)	$ (26,431)	$ (14,779)